The combination of axi-cel and rituximab showed high efficacy in refractory LBCL, with a 73% complete response rate and 88% overall response rate. Safety was favorable, with no new signals; 96% ...

Trial data on epcoritamab plus rituximab-lenalidomide, a novel CELMoD agent, late-line CAR-T cell therapy, and selecting first-line therapy are follicular lymphoma highlights from ASH 2025.

Rituximab (Rituxan) did not show noninferiority compared with ocrelizumab (Ocrevus) in relapsing-remitting multiple sclerosis (MS), according to registry data. The annualized relapse rate (ARR) was ...

Please provide your email address to receive an email when new articles are posted on . “Trial limitations included the enrollment of patients with GPA or microscopic polyangiitis, who might need to ...

Improved outcomes among breast cancer patients with more frequent mammography screening. This is an ASCO Meeting Abstract from the 2020 ASCO Annual Meeting I. This abstract does not include a full ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

Adalimumab was the most commonly used tumor necrosis factor-alpha inhibitor (TNFi), accounting for 47% of 90,000 incidences of TNFi use. Rituximab was the most commonly used non-TNFi, for 44% of ...

Rituxan (rituximab) may be prescribed for moderate to severe rheumatoid arthritis if TNF blocking agents haven’t worked, often with methotrexate. Administered intravenously in two infusions separated ...

In a new study, rituximab therapy was found to be an effective treatment option for lupus nephritis (LN) management. After six months of use, people with lupus nephritis taking the therapy showed ...